Novo Nordisk
Tracked across 70 events · 688 articles · First seen Feb 02, 2025 · Last active Aug 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Sep 10, 2025 · 6 articles
Business
Impact: Novo Nordisk partnered with Emcure Pharma to expand the distribution and marketing of its weight-loss drug semaglutide in India under the brand Poviztra, aiming to reach a wider population.
Nov 10, 2025 · 6 articles
Business
Impact: Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Nov 11, 2025 · 6 articles
Regulatory
Impact: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
Business
Impact: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Tech
Impact: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
Regulatory
Impact: Novo Nordisk is a pharmaceutical company facing multiple lawsuits alleging that its GLP-1 medications, Semaglutide and Semaglutide, caused NAION and that the company failed to adequately warn consumers about these risks. This could lead to significant financial and reputational damage.
May 22, 2026 · 7 articles
Accidents
Impact: Novo Nordisk, a pharmaceutical giant, was the target of a major cyberattack by Fulcrum Securities, resulting in the theft of over a terabyte of sensitive data. The company refused to pay a $25 million ransom, leading to potential private sales of the stolen data, which could damage its reputation, intellectual property, and patient trust.
Jun 16, 2026 · 11 articles
Business
Impact: Novo Nordisk launched Awiqli, its once-weekly insulin, in India, enhancing its product portfolio and competitive edge in the diabetes market.
Jul 09, 2026 · 21 articles
Business
Novo Nordisk is executing a share repurchase programme of up to DKK 15 billion over 12 months starting 4 February 2026. Under a sub-programme initiated 6 May 2026, the company repurchases B shares for up…
Impact: Novo Nordisk is executing the share repurchase programme, repurchasing its own B shares as part of a DKK 15 billion buyback plan.
May 26, 2026 · 22 articles
Regulatory
Impact: Novo Nordisk is the drug manufacturer; the approval expands Wegovy's indication in India, potentially increasing sales and market share in the obesity and metabolic disease market.
Jul 17, 2026 · 13 articles
Business
Impact: Novo Nordisk is the sponsor and developer of ziltivekimab; the trial failure will result in an impairment charge and may negatively impact investor sentiment, though the company maintains its 2026 outlook.
Jul 31, 2026 · 6 articles
Business
Impact: Central player; shares up 35% from March low, launching oral Semaglutide and suing Lilly, but faces competition and past profit warnings.
Aug 03, 2026 · 6 articles
Business
On August 10, 2026, Novo Nordisk and Amazon — Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernize operations through agentic AI and cloud technologies. The agreement establishes AWS as…
Impact: Novo Nordisk is the primary beneficiary, gaining access to AWS's AI and cloud capabilities to accelerate drug discovery and modernize operations, potentially improving its pipeline and efficiency.
Aug 10, 2026 · 7 articles
Business
Impact: Novo Nordisk partnered with Costco to expand access and sales of its GLP-1 medications, Semaglutide and Semaglutide, at a standardized discounted price, combating competition from compounding pharmacies.
Oct 03, 2025 · 8 articles
Domestic
Impact: Novo Nordisk's drugs, Semaglutide and Tirzepatide, are among those that will be reimbursed in France, leading to increased market access and sales for the company in Europe. The company's General Manager and CEO welcomed the decision.
May 28, 2026 · 6 articles
Regulatory
Impact: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Regulatory
Impact: Novo Nordisk developed Semaglutide (semaglutide), and its collaboration with the United Arab Emirates — Emirates Drug Establishment led to the approval of the oral formulation in the United Arab Emirates, expanding its market reach for this significant treatment.
Jun 01, 2026 · 6 articles
Domestic
Impact: Novo Nordisk's semaglutide is the drug being tested; positive results could expand its approved uses and market, though the trial is early-stage.
Jul 30, 2026 · 6 articles
Tech
Impact: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Tech
A small but growing body of research indicates that GLP-1 drugs, commonly used for obesity and diabetes, may also be effective in treating polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting 1 in 8…
Impact: Manufacturer of semaglutide, the GLP-1 drug tested in the PMOS trials; positive results could expand its approved indications and market.
Aug 15, 2026 · 12 articles
Business
Impact: Novo Nordisk is outsourcing cartridge fill-finish manufacturing services to Biopharmaceutical, which could streamline its production and supply chain.
Jun 30, 2026 · 6 articles
Tech
Impact: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
Tech
Impact: Novo Nordisk, the manufacturer of Semaglutide, is facing scrutiny due to reports of severe adverse reactions experienced by Sarah-Jayne Crawford. They have issued a statement acknowledging gallstones as a common potential adverse reaction.
Apr 13, 2026 · 6 articles
Tech
Impact: Novo Nordisk is the manufacturer of Semaglutide, and the positive research findings could lead to expanded market opportunities and increased demand for their GLP-1 drugs.
Jun 02, 2026 · 6 articles
Business
Impact: Novo Nordisk gains access to evaluate a novel delivery method for semaglutide, potentially expanding its weight management portfolio.
Jul 07, 2026 · 6 articles
Business
Impact: Novo Nordisk developed Kyinsu and sees its first global commercialization in China, expanding its diabetes treatment portfolio and market reach.
Jul 20, 2026 · 6 articles
Tech
In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, a wave of studies and media coverage suggested that GLP-1 drugs such as Ozempic might lower cancer risk. Observational studies…
Impact: As the manufacturer of Ozempic, Novo Nordisk is central to the debate. Positive observational studies could support sales, but expert caution and lack of randomized trial confirmation may limit upside. The company's stock may see volatility based on headlines.
Jul 13, 2026 · 6 articles
Regulatory
Impact: Novo Nordisk's Wegovy is one of the GLP-1 drugs being prescribed via telehealth; the study may lead to stricter oversight that could affect sales.
Jul 07, 2026 · 6 articles
Regulatory
Impact: Novo Nordisk manufactures and supplies the innovator semaglutide used in Poviztra, benefiting from expanded indications in India.
Jul 20, 2026 · 8 articles
+ 40 more events
View on Dashboard
90
Novo Nordisk initiated share repurchaseNovo Nordisk share...
90
Novo Nordisk selected as preferred cloud provider Amazon — Amazon Web ServicesNovo Nordisk AWS AI Drug...
85
Novo Nordisk threatened to sue Hims & Hers HealthFTC sues Hims & Hers over...
70
Novo Nordisk produced drugsGLP-1 drugs show promise for PMOS
70
Novo Nordisk entered strategic partnership Amazon — Amazon Web ServicesNovo Nordisk AWS AI Drug...
70
Hims & Hers Health announced collaboration Novo NordiskFTC sues Hims & Hers over...
60
Novo Nordisk will deploy Amazon (company) Bedrock AgentCore Amazon — Amazon Web ServicesNovo Nordisk AWS AI Drug...
50
Novo Nordisk collaborates with multiple Amazon (company) businesses Amazon (company)Novo Nordisk AWS AI Drug...
40
Novo Nordisk announced partnership with OpenAI OpenAINovo Nordisk AWS AI Drug...
Hims & Hers Health
competitor
↔
Novo Nordisk
Novo Nordisk terminated its distribution partnership with Hims & Hers Health and
Hims & Hers Health
competitor
↔
Novo Nordisk
Hims & Hers Health is facing legal threats from Novo Nordisk after their brief d
ERGEN INTELLIGENCE
Track Novo Nordisk live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard